TWI799432B - 抗ctla-4抗體及其用途 - Google Patents

抗ctla-4抗體及其用途 Download PDF

Info

Publication number
TWI799432B
TWI799432B TW107125627A TW107125627A TWI799432B TW I799432 B TWI799432 B TW I799432B TW 107125627 A TW107125627 A TW 107125627A TW 107125627 A TW107125627 A TW 107125627A TW I799432 B TWI799432 B TW I799432B
Authority
TW
Taiwan
Prior art keywords
ctla
antibodies
Prior art date
Application number
TW107125627A
Other languages
English (en)
Other versions
TW201920267A (zh
Inventor
艾努爾 赫爾曼
艾拉 約費
艾倫娜 布羅瓦
佳文 瑟斯頓
威廉 奧爾森
Original Assignee
美商再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商再生元醫藥公司 filed Critical 美商再生元醫藥公司
Publication of TW201920267A publication Critical patent/TW201920267A/zh
Application granted granted Critical
Publication of TWI799432B publication Critical patent/TWI799432B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
TW107125627A 2017-07-27 2018-07-25 抗ctla-4抗體及其用途 TWI799432B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762537753P 2017-07-27 2017-07-27
US62/537,753 2017-07-27
US201762588853P 2017-11-20 2017-11-20
US62/588,853 2017-11-20
US201862645284P 2018-03-20 2018-03-20
US62/645,284 2018-03-20
US201862685599P 2018-06-15 2018-06-15
US62/685,599 2018-06-15

Publications (2)

Publication Number Publication Date
TW201920267A TW201920267A (zh) 2019-06-01
TWI799432B true TWI799432B (zh) 2023-04-21

Family

ID=63165545

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107125627A TWI799432B (zh) 2017-07-27 2018-07-25 抗ctla-4抗體及其用途

Country Status (17)

Country Link
US (2) US10844137B2 (zh)
EP (1) EP3658585A1 (zh)
JP (2) JP7296363B2 (zh)
KR (1) KR20200032189A (zh)
CN (1) CN111133004B (zh)
AU (1) AU2018307675A1 (zh)
BR (1) BR112020001266A2 (zh)
CA (1) CA3070790A1 (zh)
CL (1) CL2020000216A1 (zh)
CO (1) CO2020000438A2 (zh)
IL (1) IL271882A (zh)
MA (1) MA49687A (zh)
PH (1) PH12020500078A1 (zh)
SG (1) SG11202000366WA (zh)
TW (1) TWI799432B (zh)
WO (1) WO2019023482A1 (zh)
ZA (1) ZA202000113B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CA3129963A1 (en) * 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
KR20220093349A (ko) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 흑색종에 대한 lag-3 길항제 요법
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
AU2021258257A1 (en) 2020-04-22 2022-11-10 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
KR20230035595A (ko) * 2020-07-08 2023-03-14 리제너론 파아마슈티컬스, 인크. 항-ctla-4 항체를 함유하는 안정화된 제형
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
CN116323922A (zh) * 2020-12-17 2023-06-23 南京蓬勃生物科技有限公司 筛选靶向CD47-SIRPα免疫检查点的候选药物的方法和试剂盒
AU2022253351A1 (en) 2021-04-09 2023-10-12 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2023097030A1 (en) 2021-11-24 2023-06-01 Regeneron Pharmaceuticals, Inc. Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2016196237A1 (en) * 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11917A (en) * 1998-12-23 2006-04-13 Abgenix Inc Human monoclonal antibodies to ctla-4.
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2589418A1 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
CN102471378B (zh) 2009-06-26 2014-04-02 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
SG11201606979TA (en) * 2014-03-11 2016-09-29 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2016219170B2 (en) * 2015-02-13 2021-09-09 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CTLA4
US11208483B2 (en) * 2015-11-19 2021-12-28 Shanghai Kanda Biotechnology Co, Ltd. CTLA-4 antibodies and uses thereof
CA3040924A1 (en) * 2016-12-09 2018-06-14 Regeneron Pharmaceuticals, Inc. Systems and methods for sequencing t cell receptors and uses thereof
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2016196237A1 (en) * 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof

Also Published As

Publication number Publication date
BR112020001266A2 (pt) 2020-07-28
JP2023113893A (ja) 2023-08-16
US10844137B2 (en) 2020-11-24
JP2020528750A (ja) 2020-10-01
TW201920267A (zh) 2019-06-01
MA49687A (fr) 2020-06-03
EP3658585A1 (en) 2020-06-03
US20190048096A1 (en) 2019-02-14
ZA202000113B (en) 2021-07-28
US20210040232A1 (en) 2021-02-11
CN111133004B (zh) 2023-12-01
JP7296363B2 (ja) 2023-06-22
CO2020000438A2 (es) 2020-01-31
CL2020000216A1 (es) 2020-07-10
KR20200032189A (ko) 2020-03-25
PH12020500078A1 (en) 2020-11-09
IL271882A (en) 2020-02-27
CA3070790A1 (en) 2019-01-31
SG11202000366WA (en) 2020-02-27
CN111133004A (zh) 2020-05-08
WO2019023482A1 (en) 2019-01-31
AU2018307675A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
TWI799432B (zh) 抗ctla-4抗體及其用途
EP3383916A4 (en) ANTI-CD73 ANTIBODIES AND USES THEREOF
EP3625263A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
EP3325513A4 (en) Anti-pd-l1 antibodies and uses thereof
EP3723803A4 (en) ANTI-TREM2 ANTIBODIES AND RELATED METHODS
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND THEIR USES
EP3400243A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
EP3762030A4 (en) ANTI-CD73 ANTIBODIES AND USES THEREOF
EP3733704A4 (en) Anti-pd-l1 antibody and uses thereof
EP3596119A4 (en) ANTI-PHF-TAU ANTIBODIES AND USES THEREOF
EP3389702A4 (en) ANTI-LAG-3 ANTIBODIES AND USES THEREOF
EP3571231A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF
EP3328895A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF
EP3426288A4 (en) ANTI-PACAP ANTIBODIES AND USES THEREOF
EP3684812A4 (en) ANTI-CTLA4 ANTIBODIES AND USES THEREOF
EP3587453A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
EP3891183A4 (en) ANTI-CLAUDINE ANTIBODIES AND THEIR USES
EP3733702A4 (en) ANTI-LAG-3 ANTIBODIES AND USES THEREOF
EP3645563A4 (en) ANTI-FAM19A5 ANTIBODIES AND THEIR USES
EP3735427A4 (en) ANTI-MCT1 ANTIBODIES AND ASSOCIATED USES
EP3672987A4 (en) ANTI-APELINE ANTIBODIES AND THEIR USES
EP3402520A4 (en) Anti-pd-1 antibodies and uses thereof
EP3790586A4 (en) ANTI-DLL3 ANTIBODIES AND USES THEREOF
EP3562508A4 (en) ANTI-BODY ANTI-LAIR1 AND THEIR USES